S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Corticosteroids for cancer-related pain in adults Patient or population: adult patients with cancer-related pain Settings: in-and out-patients Intervention: corticosteroids
Outcomes
Illustrative comparative risks* (95% CI) Relative effect (95% CI)
No of participants (studies)
Quality of the evidence (GRADE)
Comments
Assumed risk Corresponding risk
Control Corticosteroids
Pain at 1 week Scale from: 0 to 10
The mean pain at 1 week in the control group was 3.77
The mean pain at 1 week in the intervention groups was 0.84 lower (1.38 Pain (1 to 10) with lower score indicating less pain Quality of evidence low due to the small number of participants in each arm for the included studies *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality:
We are very uncertain about the estimate.
B A C K G R O U N D

Description of the condition
Cancer remains the leading cause of death worldwide. Over 12 million new cases are diagnosed each year (Foley 2011). The disease carries significant morbidity. Pain resulting directly or indirectly from the abnormal growth of malignant cells in normal tissue is the most common and most feared symptom associated with cancer (Van den Beuken-van Everdingen 2007). It is estimated that one-third of cancer patients on active therapy, and twothirds of those with advanced disease, experience pain that requires treatment with analgesic drugs (Foley 2011). Of concern, there is also considerable evidence that cancer pain is often under treated (Foley 2011). While opioids remain the mainstay of treatment for cancer pain, co-analgesics or adjuvants are often used concurrently to optimise pain control. Corticosteroids (steroids) are commonly used in this context.
Description of the intervention
Steroids are essential for maintaining homeostasis and regulating a wide variety of physiological processes in the human body (Busillo 2013). Therapeutically, they are widely prescribed for the treatment of inflammation, auto-immune disorders and malignancies (Busillo 2013). They are commonly used in the management of cancer pain.
How the intervention might work
Corticosteroids are used for relief of pain associated with spaceoccupying lesions, not only in the brain, spinal cord and nerves, but also in the liver and soft tissues (eTG Complete 2014). They are used where there may be inflammation and oedema in confined spaces, including intracerebral, pelvic, retroperitoneal and spinal malignant disease, and are often used as an interim measure while awaiting more definitive therapies such as radiotherapy (eTG Complete 2014). Corticosteroids have been proposed to have effects on all four stages of pain nociception including transduction, transmission, modulation and pain perception, although the exact mechanisms remain unclear (Leppert 2012). The anti-inflammatory effect of corticosteroids may be due to (i) inhibition of the expression of collagenase, an enzyme involved in tissue degeneration during inflammatory mechanisms, (ii) inhibition of pro-inflammatory cytokines, which have been implicated in a number of pain states, or (iii) by stimulating the synthesis of lipocortin, which in turn blocks the production of eicosanoids (Leppert 2012; Paulsen 2013). It is proposed that the mechanism of pain relief for cancer-related neuropathic pain is by the inhibition of prostaglandin production, reduction of inflammation thus decreasing capillary permeability and reducing oedema (Pharo 2005) In summary, the mechanism of action of corticosteroids in the reduction of cancer pain remains unclear.
Why it is important to do this review
Corticosteroids are prescribed frequently in oncology practice to reduce swelling and pain caused by cancer and may also be used to control and prevent nausea and vomiting caused by chemotherapy. In addition, it is common in palliative care practice, especially for patients with advanced malignant disease, for a variety of symptom control indications including pain, nausea, mood elevation, anorexia and fatigue (Farr 1990; Hardy 2001; Riechelmann 2007) . This is despite the fact that steroids are associated with significant side effects, especially following long-term use (Hanks 2009). There is little objective evidence in the literature to support the use of corticosteroids for symptom control, and concerns have been raised about the 'uncontrolled' use of steroids in cancer patients (Gannon 2002; Twycross 1985) . Patients who are started on steroids in the palliative care setting are often not closely monitored, allowing for the development of debilitating side effects, often in the context of limited clinical benefit. Some of these side effects include: proximal myopathy, oral candidiasis, symptomatic hyperglycaemia, psychological disturbances, gastrointestinal irritation, increased susceptibility to infections and the development of osteoporosis. For example, although steroids are frequently administered to assist with mood elevation, some studies have shown that corticosteroid therapy may result in more disturbing side effects such as insomnia, delirium, depression, anxiety and psychosis (Vyvey 2010). There is a relevant gap in the body of knowledge, in that most patients with cancer will be prescribed steroids at some stage during their disease course with very little evidence of effectiveness.
O B J E C T I V E S
To evaluate the efficacy of corticosteroids in treating cancer-related pain in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Any randomised controlled or prospective controlled trial.
Types of participants
Participants with cancer-related pain, aged 18 years and above.
Types of interventions
Types of interventions included any corticosteroid used to treat cancer-related pain. We considered all routes of drug administration. Comparisons were:
• placebo;
• no intervention;
• usual treatment or supportive care; or • non-pharmacological treatment for pain.
Types of outcome measures
Primary outcomes
• Patient-reported pain intensity and pain relief using validated scales (visual analogue scale (VAS), verbal rating scale (VRS), numerical rating scale (NRS)).
Secondary outcomes
• Adverse events • Quality of life • Patient satisfaction • Other relevant outcome measures, e.g. cost-effectiveness data
Search methods for identification of studies
The search strategy attempted to identify as many trials as possible that met the inclusion criteria without limitation by language, publication type or status or by date.
Electronic searches
We searched the following electronic databases: The Cochrane Highly Sensitive Search Strategy (CHSS) filter for identifying randomised trials in MEDLINE via OVID was also modified and applied. This search was adapted and modified across the other databases. The search strategies are shown in Appendices 1 to 4 (Appendix 1; Appendix 2; Appendix 3; Appendix 4).
Searching other resources
We checked the bibliographic references of any relevant identified studies in order to find additional trials not identified by the electronic searches. We also searched www.ClinicalTrials.gov, the metaRegister of Controlled Trials (mRCT www.controlledtrials.com/mrct/), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) ( apps.who.int/trialsearch/) to identify any ongoing trials. In order to identify any unpublished or grey literature, we searched the Internet using the Google Scholar search engine ( www.googlescholar.com), with selected terms from the above strategy. If only the abstract was published, we attempted to contact the authors for further details or for the unpublished paper. The searches were conducted by one of the review authors (KR) who is a Librarian. All searches were current as of 29 September 2014.
Data collection and analysis
Selection of studies
Four of the review authors (JH, PG, SJ-M, KR) independently assessed the titles and abstracts of all the studies identified by the search for potential inclusion. Each of these authors independently selected all potentially relevant studies for inclusion by applying the selection criteria outlined in the 'Criteria for considering studies for this review' section. We then compared these four lists, discussed any differences and either included or excluded the papers based on a majority decision. A PRISMA study flow diagram (Liberati 2009) is included in Figure 1 to document the screening process, as recommended in Part 2, Section 11.2.1 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). 
Data extraction and management
Four review authors (AL, AH, SK, SJ-M) independently extracted data from the studies, using a piloted data extraction form. Data extracted included information about the year of study, study design, number of participants treated, participant demographic details, type of cancer, drug and dosing regimen, study design (placebo or active control) and methods, study duration and follow-up, outcome measures (measurement of pain, pain scale), withdrawals and adverse events. We resolved potential disagreements by discussion.
Assessment of risk of bias in included studies
Six of the authors (AL, AH, JH, PG, SK, KR) independently assessed the risk of bias of each of the included studies by using the 'Risk of bias' assessment method outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved potential disagreements by discussion. For each study we assessed the risk of bias for the following domains.
1. Random sequence generation (checking for selection bias). 2. Allocation concealment (checking for selection bias). 3. Blinding of participants and personnel (checking for performance bias).
4. Blinding of outcome assessment (checking for detection bias).
5. Incomplete outcome data (checking for attrition bias). 6. Selective reporting (checking for reporting bias). 7. Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (200 or more participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm). We used the GRADE approach to assess the overall quality of the evidence for the primary outcome, with downgrading of the evidence from 'high quality' by one level for serious (or by two for very serious) study limitations (risk of bias), indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias (Langendam 2013). The outcome included in the 'Summary of findings' table was pain at week one (Summary of findings for the main comparison).
Measures of treatment effect
For continuous outcomes between groups, we measured arithmetic means and standard deviations (SD) and reported the mean difference (MD) with 95% CI. When an outcome was derived with different instruments measuring the same construct, we used the standardised mean difference (SMD) with 95% CIs.
Unit of analysis issues
We only included studies in which randomisation was by the individual patient; this included cross-over or n = 1 studies.
Dealing with missing data
In cases where data were missing, we attempted to contact the authors to request the missing data. This strategy did not result in any additional data. We ascertained the method of assessing data processed from withdrawals where possible. It was not possible to assess the impact of missing data in sensitivity analyses due to the low study numbers. In all cases we aimed to perform intentionto-treat analyses.
Assessment of heterogeneity
There may be an effect of differences between patients, environment (inpatient versus outpatient) and outcome measures. We assessed heterogeneity by using the I 2 statistic. We considered I 2 values above 50% to represent substantial heterogeneity, in line with Higgins 2011, and assessed potential sources of heterogeneity through subgroup analyses.
Assessment of reporting biases
We interpreted the results of tests in the light of visual inspection of the funnel plot. If there was evidence of small study effects, we considered publication bias as only one of a number of possible explanations (Higgins 2011).
Data synthesis
We entered the data extracted from the included studies into Review Manager (RevMan 2014), which we used for data synthesis. Where appropriate, we pooled data for each dichotomous outcome and calculated RRs with 95% CIs using a random-effects model.
Sensitivity analysis
When sufficient data were available, we examined the robustness of the meta-analyses by conducting sensitivity analyses using different components of the 'Risk of bias' assessment, particularly those relating to whether allocation concealment and patient/assessor blinding were adequate. We conducted further sensitivity analyses to examine the impact of missing data on the results as a large proportion of the studies are at an 'unknown' or 'high' risk of attrition bias and, finally, sensitivity analyses to examine whether publication status and trial size influenced the results. Unfortunately, due to the low number of studies within each comparison, we were unable to perform any sensitivity analyses.
R E S U L T S
Description of studies
See: 'Characteristics of included studies' and 'Characteristics of excluded studies' tables.
Results of the search
The PRISMA diagram ( Figure 1 ) outlines the number of records identified in the search and the screening process for these papers. In the initial database search we identified 5891 records. Of these, 743 were duplicates and we rejected 5107 based on information given in the title and abstract. We identified 41 publications for full-text retrieval. We excluded 26 of these studies during screening. In three studies, only the abstract had been published and, as further detail was unavailable, we excluded them. Seven studies did not satisfy the inclusion criteria and we excluded 16 because pain was not an endpoint. The reasons for exclusion of each study are described in the 'Characteristics of excluded studies' table. A total of 15 studies met the inclusion criteria for this review. These included six placebo-controlled studies, one placebo-controlled cross-over study, five studies with active controls, one open-label and two low-dose versus high-dose studies ( Table 1) 
Primary disease sites
The primary disease sites addressed are tabulated in Table 2 . Most of the trials did not include patients with a specific cancer type, with the exception of Fossa 2001, Lee 2008 and Teshima 1996.
Types of studies
Studies were included in which steroids were used as part of a treatment regimen and pain was assessed as an outcome (Fossa 2001; Lee 2008). Two studies tested high-dose versus low-dose steroids (Graham 2006; Vecht 1989).
Pain requirement as an entry criteria
Eight of the 15 studies required that participants had pain at study entry ( Table 3 .
Pain and analgesic measurement tools
Different measurement tools were used to measure pain intensity.
• 
Risk of bias in included studies
We assessed each study using the Cochrane 'Risk of bias' tool. Overall findings are presented in the 'Risk of bias' graph ( Figure  2 ), which reviews the authors' judgements about each risk of bias item presented as percentages across all included studies. Authors' judgements about each risk of bias for each included study is shown in 'Risk of bias' summary ( Figure 3 ).
Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as
percentages across all included studies.
Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
Allocation
All studies reported that they were randomised, but only six out of 15 properly described the method used to generate the random sequence. Four studies were randomised using a computer program (Della 1989; Lauretti 2013; Paulsen 2014; Popiela 1989). The participants from Graham 2006 were randomised using the Superdex website. Those from Teshima 1996 were randomly allocated according to Peto's balanced randomised list. We judged the six studies describing randomisation to have low risk and the other nine to have unclear risk of bias. We judged seven studies to be low risk for allocation concealment; the trial medications were of identical appearance ( A total of 372 patients at baseline and 315 patients after one week of intervention were involved in these six studies. After one week of intervention, the intervention arm was favoured in all trials ( Figure  4 ). The total mean difference is -0.84 with a 95% confidence interval of -1.38 to -0.30 (Analysis 1.1). While the study by Bruera 1985 was a cross-over trial, inclusion in the meta-analysis did not affect the overall review findings. 
Effects of interventions
Secondary outcomes
A meta-analysis for secondary outcomes could not be undertaken as the data were heterogeneous with no consistency of measurement tools or outcome measures. Patient satisfaction and cost-effectiveness data was not available.
Adverse events
Not all studies included information on adverse events and several reported no or only minimal adverse events compared to controls or placebo ( 
D I S C U S S I O N
Summary of main results
The objective of this systematic review was to assess whether corticosteroids are effective in reducing cancer-related pain. Fifteen randomised controlled trials with 1926 enrolled participants were included; six placebo-controlled studies, one placebo-controlled cross-over study, five studies with active controls, one open-label study and two low-dose versus high-dose studies. Included studies assessed either dexamethasone (at doses of 8 mg and 20 mg in an oral tablet or 4 mg/ml, 10 mg, 16 mg, 40 mg, 96 mg and 100 mg intravenously), methylprednisolone (16 mg and 32 mg orally or 125 mg and 500 mg intravenously) or prednisone 15 mg or prednisolone 20 mg orally. For the meta-analysis only six studies could be evaluated for pain intensity. Data were reported after one week of intervention, since this was the only time that could be standardised across all six trials. The following conclusion regarding the effectiveness of corticosteroids for pain relief in cancer patients should be interpreted with consideration of the small number of eligible studies. The quality of studies was generally poor with a high risk of bias identified.
• There is some evidence to suggest that there is a benefit in favour of the use of corticosteroids (mean difference (MD) -0.84, 95% confidence interval (CI) -1.38 to -0.30) for cancer pain for up to one week of intervention. However, it is debatable if the reduction of a mean pain score of 0.8 with wide confidence intervals is clinically meaningful.
• There were insufficient data to evaluate different subgroups such as drug type, route of administration, dosage and different primary disease types.
Further trials with increased numbers of participants are needed to evaluate the safety and effectiveness of corticosteroids for the management cancer pain in adults, and to establish an ideal dose, duration of therapy and route of administration.
Overall completeness and applicability of evidence
We identified 15 studies that met the inclusion criteria, but included only six studies in the meta-analysis for pain intensity with insufficient data available for the remaining studies. We did not attempt to classify specific pain syndromes. There were insufficient data for subgroup analyses. Statistical analysis in relation to pain intensity in this review was limited by a number of factors. There is a lack of standardised measurement of pain. Several different tools have been used for pain measurement. In the meta-analysis, visual analogue scale scores (0 to 10) and numerical scale scores (0 to 10) were compared. The results are also influenced by differences in steroid type, dosage, comparators, routes of administration, primary disease type, aetiology of pain and heterogeneity of study populations. One of the studies had a single dose of intravenous dexamethasone as an intervention compared to multiple oral doses of dexamethasone or methylprednisolone. Comparators included in the meta-analysis included both "standard treatment" (two studies) and placebo (four studies). Trials where dexamethasone was used primarily as an anticancer treatment rather than as a co-analgesic were also included.
Reporting of data
Basile 2012 reported clear data for pain outcomes at baseline and after one week of intervention. Adverse events were not reported. Bruera 1985 tabulated the intensity of pain (VAS), adverse events and quality of life in each group at baseline and after one week of intervention. Bruera 2004 presented mean pain scores, intensity of nausea and fatigue, as well as quality of life scores for both patient groups. Della 1989 presented graphical representation of mean change from baseline in Nurses' Observation Scale for Inpatient Evaluation (NOSIE) and linear analogue scale assessment (LASA) total score. No standard deviation was provided. Fossa 2001 presented data in the form of graphs. No original data were presented and it was therefore not possible to include this trial in the meta-analysis. Graham 2006 published graphical representation of pain scores. Standard deviations were missing and therefore the trial could not be included in the meta-analysis. Lauretti 2013 was not included in the meta-analysis as data on measured pain scores were not presented. Lee 2008 had missing data on mean pain intensity and standard deviation. The study was not included in the meta-analysis. Mercadante 2007 tabulated the mean scores and 95% CI for pain intensity, intensity of nausea, fatigue, drowsiness and also quality of life scores. Paulsen 2014 reported clear data for pain outcomes, fatigue and appetite at baseline and after one week of intervention. Popiela 1989 published a graphical representation of adverse events and quality of life. No data were presented on pain intensity scores, therefore the study could not be included in the metaanalysis. Teshima 1996 presented pain scores and quality of life in a graphical field, but no standard deviation was provided. The trial was not included in the meta-analysis. Twycross 1985 tabulated pain intensity scores. These could not be included in the meta-analysis as only the difference in outcome was reported at day eight with no baseline data available. Vecht 1989 presented average pain scores and standard deviation assessed by a numerical rating scale in graphical form. No original data were presented and therefore it was not possible to include it in the meta-analysis. Yennurajalingam 2013 presented the mean and standard deviation of pain intensity, nausea, depression, fatigue, drowsiness and quality of life.
Quality of the evidence
The quality of the evidence was low. This is due to imprecision (likely selection bias and the small number of patients) in the included studies. Nine studies did not adequately describe sequence generation and one study did not provide information about allocation concealment. In five studies the blinding of participants and personnel was not provided and in four studies the outcome assessment was not blinded. In a number of studies it appeared that additional pertinent outcomes should have been reported and in two studies a risk of bias in selective reporting was identified. Sample size was of concern. Only one study had more than 200 participants in each arm. Ten studies had fewer than 50 participants in each arm.
Potential biases in the review process
Data extraction, including 'Risk of bias' assessment, was done independently by all authors to minimise bias. The conclusion that can be drawn is limited by the number and the quality of the included studies. Several trials were susceptible to bias and hampered by incomplete outcome data and small sample size.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
The evidence of the efficacy of corticosteroids for pain control in cancer patients is weak. Our meta-analysis of studies with data at one week suggests that corticosteroids may relieve cancer pain, even if only for a short period of time. However, it is debatable if the reduction of a mean pain score of 0.8 with wide confidence intervals is clinically meaningful. In addition, any evidence of the efficacy of corticosteroids in the reduction of cancer pain must be weighed up against the associated significant side effects. Furthermore, we can make no recommendation regarding type of steroid, dose, route of delivery, side effect profile or treatment period.
In light of the above, we recommend that clinicians are cautious in their prescribing of steroids for pain management, that they assess benefit carefully, treat for the shortest possible time and discontinue early in the absence of symptom relief.
Implications for research
Further trials with increased numbers of participants are needed to evaluate the safety and effectiveness of corticosteroids for the management cancer pain in adults, and to establish an ideal dose, duration of therapy and route of administration. Further adequately powered randomised controlled trials with pain as a primary outcome, measured with universally accepted standardised tools, using a single agent (dexamethasone), at a pre-specified dose and route over a short time period are indicated. Longer-term toxicity should be documented during a follow-up period.
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R E F E R E N C E S
References to studies included in this review
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Basile 2012 Heterogeneity: Tau 2 = 0.21; Chi 2 = 9.72, df = 5 (P = 0.08); I 2 =49%
Methods
D A T A A N D A N A L Y S E S
Test for overall effect: Z = 3.03 (P = 0.0024) Test for subgroup differences: Not applicable -10 -5 0 5 10
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We updated the methods of the review to include the GRADE approach to assess the overall quality of the evidence for the primary outcome. There were insufficient data to evaluate different subgroups for this review, however we will perform subgroup analysis in any updated versions of this review. We will perform intention-to-treat analysis where possible in future updates.
